Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

aim immunoTech CEO buys $2,680 in company stock

aim immunoTech CEO buys $2,680 in company stock

AIM ImmunoTech Inc.'s CEO and President, Thomas K Equels, recently increased his stake in the company by acquiring 20,000 shares at a price of $0.134 per share, totaling $2,680. This insider purchase, reported on November 18, 2026, brings Mr. Equels' direct ownership of AIM ImmunoTech common stock to 386,095 shares. The move comes as the company's stock trades near its 52-week low of $0.12, down about 90% in the past year.

Despite the significant drop, InvestingPro analysis suggests the stock is undervalued at its current level, trading below the platform's Fair Value estimate. The company's balance sheet shows stronger liquidity with more cash than debt, though profitability challenges persist. Investors can explore further insights through 13 additional ProTips and detailed financial metrics on the InvestingPro platform.

Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

This story

This is one outlet's version. Read the fullest account.

Every outlet that reported this, and when →

Read the original at investing.com →